KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Non-Current Liabilities (2016 - 2025)

NovoCure's Total Non-Current Liabilities history spans 12 years, with the latest figure at $240.6 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 93.73% year-over-year to $240.6 million; the TTM value through Dec 2025 reached $240.6 million, up 93.73%, while the annual FY2025 figure was $240.6 million, 93.73% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $240.6 million at NovoCure, down from $243.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $681.2 million in Q2 2024 and bottomed at $124.2 million in Q4 2024.
  • The 5-year median for Total Non-Current Liabilities is $586.0 million (2021), against an average of $469.2 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 1932.01% in 2021 before it plummeted 79.45% in 2024.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $586.4 million in 2021, then grew by 0.9% to $591.7 million in 2022, then grew by 2.17% to $604.5 million in 2023, then tumbled by 79.45% to $124.2 million in 2024, then soared by 93.73% to $240.6 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Total Non-Current Liabilities are $240.6 million (Q4 2025), $243.9 million (Q3 2025), and $146.8 million (Q2 2025).